Probiotic foods impact gut microbes to reduce number of unhealthy bacteria

(NaturalNews) Eating fermented foods high in probiotics may change the composition of gut bacteria in ways that may prevent or alleviate digestive conditions such as irritable bowel syndrome (IBS), according to a study conducted by researchers from the French National Institute for...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news

Related Links:

Authors: Niewinna K, ZieliƄska A, Fichna J Abstract Introduction: Irritable bowel syndrome (IBS) is a complex functional gut disorder that typically manifests in early adult years. More than a third of IBS patients are diagnosed with predominant constipation subtype (IBS-C). This syndrome has a distressing impact on the quality of life and is challenging both for patients and physicians.Areas covered: This review focuses on the pathophysiology of constipation in IBS and presents current management options. It also covers the latest findings that may lead to novel pharmacological options in IBS-C management. The au...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
(Natural News) Many people with irritable bowel syndrome (IBS) often rely on doctor-prescribed drugs like laxatives, which often cause other harmful side effects. Among other natural and safe ways to manage IBS, researchers also suggest talking therapy. Researchers at the University of Southampton in the U.K., together with colleagues at King’s College London, found that talking...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
Source: Gastroenterology - Category: Gastroenterology Authors: Source Type: research
CONCLUSIONS: There is currently not enough evidence to assess whether biofeedback interventions are effective for controlling symptoms of IBS. Given the positive results reported in small trials to date, biofeedback deserves further study in people with IBS. Future research should include active control groups that use high provider-participant interaction, in an attempt to balance non-specific effects of interventions between groups, and report both commonly used outcome measures (e.g. IBS-SSS) and historical outcome measures (e.g. the composite primary symptom reduction (CPSR) score) to allow for meta-analysis with previ...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
We examined the association between DII score and odds ...
Source: Nutrition Journal - Category: Nutrition Authors: Tags: Research Source Type: research
Publication date: Available online 9 November 2019Source: Clinica Chimica ActaAuthor(s): Kamyar Khoshnevisan, Elham Honarvarfard, Farzad Torabi, Hassan Maleki, Hadi Baharifar, Farnoush Faridbod, Bagher Larijani, Mohammad Reza KhorramizadehAbstractSerotonin (5-hydroxytryptamine, 5-HT) is an important neurotransmitter which plays a significant role in various functions in the body, such as appetite, emotions, and autonomic functions. It is well known that biomarker 5-HT levels can be correlated to several diseases and disorders such as depression, anxiety, irritable bowel, and sleep trouble. Among various methods for detecti...
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
Authors: Wilder-Smith CH, Drewes AM, Materna A, Olesen SS Abstract Objectives: Mast cell involvement is evident in functional gastrointestinal disorders (FGID). FGID and mast cell activation syndrome (MCAS) are associated with multi-organ symptoms. An overlap has not been assessed.Methods: MCAS symptoms were determined by questionnaires in 2083 FGID patients.Results: The median number of MCAS symptoms ([IQR] (range 0-16)) was 6 [4-8] in all FGID, and in functional dyspepsia (FD) patients, 7 [5-9] in overlapping irritable bowel syndrome and FD (IBS+FD), 5 [3-8] in IBS and 5 [3-6] in non-IBS/non-FD (p 
Source: Scandinavian Journal of Gastroenterology - Category: Gastroenterology Tags: Scand J Gastroenterol Source Type: research
AbstractIrritable bowel syndrome (IBS) is a functional bowel disorder characterized by abdominal pain and alterations in stool form and/or frequency, leading to reduced quality of life. Pharmacologic agents currently approved by the US Food and Drug Administration for treatment of IBS with diarrhea (IBS-D) in adults are the nonsystemic antibiotic rifaximin, the mixed µ- and κ-opioid receptor agonist/δ-opioid antagonist eluxadoline, and the selective serotonin 5-HT3 antagonist alosetron (the last of which is indicated only in women with severe IBS-D refractory to conventional therapy). Both eluxadoline and...
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
AbstractPurpose of ReviewGluten is a commonly ingested polymeric protein found in wheat, barley, and rye that has gained recent notoriety because of its relationship to disease and health. Avoidance of gluten is appropriate in patients with a diagnosed gluten –related disorder and may have treatment implications in other diseases of the digestive tract. This review highlights current knowledge of gluten related disorders and the use of a gluten-free diet in gastrointestinal disease management.Recent FindingsGluten-free diets should be used in patients with a diagnosed gluten –related disorder including celiac d...
Source: Current Treatment Options in Gastroenterology - Category: Gastroenterology Source Type: research
Arthur Beyder, M.D., Ph.D., runs a research laboratory at Mayo Clinic focused on examining the molecular mechanisms of gastrointestinal function and dysfunction in diseases such as irritable bowel syndrome. His goal is to discover better ways to diagnose and treat these conditions, including individualized treatment options. Using the patch-clamp technique to study the mechanical and electrical properties of sensory cells. "These [...]
Source: News from Mayo Clinic - Category: Databases & Libraries Source Type: news
More News: Irritable Bowel Syndrome | Study